Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pregabalin: From molecule to medicine.

Richard Kavoussi1

  • 1Pfizer Global Research and Development, Ann Arbor, MI 48105, USA. Richard.Kavoussi@pfizer.com

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|June 13, 2006
PubMed
Summary

Pregabalin effectively treats generalized anxiety disorder (GAD) by modulating voltage-gated calcium channels. This novel mechanism offers anxiolytic effects similar to existing treatments, with rapid onset.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term efficacy of pregabalin in generalized anxiety disorder.

International clinical psychopharmacologyยท2007
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Generalized Anxiety Disorder (GAD) poses a significant clinical challenge.
  • Existing treatments like benzodiazepines and venlafaxine have limitations.
  • Pregabalin is an anticonvulsant with demonstrated efficacy in neuropathic pain.

Purpose of the Study:

  • To elucidate the mechanism of action (MOA) of pregabalin.
  • To evaluate pregabalin's efficacy in treating Generalized Anxiety Disorder (GAD).
  • To compare pregabalin's anxiolytic effects with established treatments.

Main Methods:

  • Clinical trials involving patients with GAD.
  • Assessment of anxiolytic effects, including psychic and somatic symptoms.
  • Pharmacological studies investigating pregabalin's interaction with voltage-gated calcium channels (VGCCs).

Main Results:

  • Pregabalin demonstrated efficacy comparable to benzodiazepines and venlafaxine in GAD.
  • Anxiolytic effects were observed as early as Week 1 of treatment.
  • Pregabalin selectively binds to the alpha-2-delta subunit of VGCCs, modulating neurotransmitter release.

Conclusions:

  • Pregabalin's novel MOA involves the modulation of hyper-excited VGCCs.
  • This mechanism underlies its anxiolytic, analgesic, and anticonvulsant properties.
  • Pregabalin presents a well-tolerated and effective therapeutic option for GAD.

Related Experiment Videos